CPC A61K 35/74 (2013.01) [A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 31/34 (2013.01); A61K 31/427 (2013.01); A61K 31/439 (2013.01); A61K 31/4418 (2013.01); A61K 31/513 (2013.01); A61K 31/52 (2013.01); A61K 31/5377 (2013.01); A61K 31/675 (2013.01); A61K 31/702 (2013.01); A61K 31/7072 (2013.01); A61K 31/715 (2013.01); A61K 38/162 (2013.01); A61K 38/212 (2013.01); A61K 45/06 (2013.01); A61K 47/60 (2017.08); A61P 31/18 (2018.01); C07H 3/06 (2013.01); C08B 37/0003 (2013.01)] | 16 Claims |
1. A method of treating one or both of HIV and HBV in a subject in need thereof, comprising: administering to the subject an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a glycan strand comprising GlcNAc-MurNAc (G-M), MurNAc-GlcNAc-MurNAc (M-G-M), and GlcNAc-MurNAc-GlcNAc-MurNAc (G-M-G-M).
|